Product
Dexrazoxane
Aliases
Cardioxane, Dexrazoxane Hydrochloride, Totect, Zinecard
Name
Dexrazoxane
INN Name
Dexrazoxane for Injection
FDA Approved
Yes
11 clinical trials
6 organizations
36 indications
1 document
Indication
Diffuse Large B Cell LymphomaIndication
SarcomaIndication
HealthyIndication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesIndication
de NovoIndication
SecondaryIndication
Previously TreatedIndication
Therapy-Related Myelodysplastic SyndromeIndication
Acute Lymphoblastic LeukemiaIndication
RelapseIndication
Lymphoblastic LymphomaIndication
RefractoryIndication
Acute Leukemia of Ambiguous LineageIndication
Ewing SarcomaIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
BCR-ABL1-positiveIndication
Myelodysplastic SyndromeIndication
Myeloid SarcomaIndication
Myeloproliferative NeoplasmIndication
Philadelphia Chromosome PositiveIndication
Childhood Solid NeoplasmIndication
NeuroblastomaIndication
Soft TissueIndication
Soft Tissue SarcomaIndication
Undifferentiated Pleomorphic SarcomaIndication
LeiomyosarcomaIndication
LiposarcomaIndication
Synovial SarcomaIndication
MyxofibrosarcomaIndication
AngiosarcomaIndication
fibrosarcomaIndication
Malignant Peripheral Nerve Sheath TumorIndication
Epithelioid SarcomaIndication
Mixed Phenotype Acute LeukemiaClinical trial
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label TrialStatus: Not yet recruiting, Estimated PCD: 2028-12-15
Clinical trial
A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk RhabdomyosarcomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast CancerStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 MutationsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-04-02
Clinical trial
A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing SarcomaStatus: Active (not recruiting), Estimated PCD: 2027-05-01
Clinical trial
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaStatus: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2017-01-01
Clinical trial
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-07-17
Clinical trial
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy BackbonesStatus: Recruiting, Estimated PCD: 2027-09-30
Organization
Gland Pharma LimitedOrganization
AuroMedics Pharma LLCDocument
DailyMed Label: DexrazoxaneOrganization
Breckenridge Pharmaceutical, Inc.Organization
Fosun Pharma USA Inc.Organization
ALMAJECT, INC.Organization
Eugia US LLC